In agreement with these observations, loss of ZC3H18 reduces BRCA1 levels, disrupts HR, and sensitizes ovarian cancer cells to the DNA crosslinking agents, cisplatin and melphalan, as well as the PARP inhibitors veliparib and olaparib. Here, ZC3H18 is linked to ovarian carcinoma.